Explore Business Standard
Cipla
Cipla Ltd has inked an exclusive agreement with Pfizer India to market, distribute, and sell the latter's four brands across the country. Under the agreement, Cipla now has the sole right to market, distribute and sell the cough syrup Corex Dx and Corex LS, the non-steroidal anti-inflammatory drug (NSAID) Dolonex, proton pump inhibitor (PPI) Neksium and the oral antibiotic Dalacin C in India, the two companies said in a joint statement on Friday. Pfizer will continue to manufacture, source, and supply these medicines to Cipla for India, they added. It is the first partnership between Pfizer and Cipla in India. The agreement aims to make Pfizer's medicines widely available across India by combining its well-established portfolio with Cipla's deep market reach, the statement said. Pfizer India Country President Meenakshi Nevatia said the partnership with Cipla will help expand the reach of its medicines to patients. "With Pfizer's legacy of breakthroughs, quality and innovation, and
Pharma major Cipla Ltd on Thursday reported a 3.7 per cent rise in consolidated net profit at Rs 1,353.37 crore for the second quarter ended September 30, 2025. The company had posted a consolidated net profit of Rs 1,305.01 crore in the second quarter of the last fiscal year, Cipla Ltd said in a regulatory filing. Consolidated total revenue from operations in the second quarter stood at Rs 7,589.44 crore, as against Rs 7,051.02 crore in the year-ago period, it added. Total expenses in the quarter under review were higher at Rs 6,004.86 crore, as compared to Rs 5,452.57 crore in the corresponding period last fiscal, the company said. In the second quarter, the pharmaceuticals segment clocked revenue of Rs 7,291.43 crore, as against Rs 6,775.56 crore in the same period a year ago. New ventures registered revenue of Rs 350.68 crore, as against Rs 319.6 crore, the filing said.